o GeoVax vaccines were well tolerated with no or mild local and
systemic reactions in the majority of trial participants.
o 80 percent of both the low and full dose trial participants
responded to the vaccine which stimulated anti-HIV T-cell
(white blood cell) and antibody responses.
o More volunteers had antibody responses to the full dose than to
the 1/10th dose vaccine, whereas response rates for T cells
were similar for the 1/10th and full dose.
o Two DNA primes were more effective than one DNA prime or no DNA
primes at eliciting T cell responses.
o The 2nd MVA vaccination positively increased CD8 T cell and
Dr. Harriet Robinson, the developer of the vaccine and GeoVax's Vice
President of Research and Development, also presented these same results at
the Viral Vector Vaccines 2008 meeting, at the Wellcome Trust Conference
Center near Cambridge, UK, on September 28, 2008.
* In August 2008, GeoVax announced the appointment of Mr. Peter
Tsolinas to its Board of Directors. Mr. Tsolinas also was
subsequently appointed to membership on GeoVax's Audit Committee and
Compensation Committee. Mr. Tsolinas currently serves as Chairman
and CEO of TMA Group Development Corp., a Chicago-based real estate,
architectural and development firm.
* In July 2008, GeoVax and Vivalis S.A., a French biopharmaceutical
company that provides innovative cell-based solutions to the
pharmaceutical industry for the manufacture of vaccines and
proteins, jointly announced the signing of a letter of intent for
joint collaboration and commercial license on the use of Vivalis'
|SOURCE GeoVax Labs, Inc.|
Copyright©2008 PR Newswire.
All rights reserved